Overview

A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

Status:
Not yet recruiting

Trial end date:
2023-06-08

Target enrollment:

Participant gender:

Summary

This study will assess the relative bioavailability of the CAB DT formulation relative to that of the CAB IR formulation and to assess the effect of food on the CAB DT formulation.

Phase:

Phase 1

Details

Lead Sponsor:

ViiV Healthcare

Treatments:

Cabotegravir